Table 3.
Open in new tab

Baseline Table of All Studies

StudyDesignLevelNo. patientsTreat groupAge(y)BMI kg/m2No. sessionsFellow-up (mo)Satisfaction No. PatientsSatisfaction No. SurgeonNo. ComplicationsNo. BiopsyMean Volume injection (ml)Volume retention(%)
Abboud and Dibo, 201524CH2b80AFT362612465 (n = 72)—11 (n = 160)1 (n = 160)42059.4% (12m)
Auclair, 2009CS41433AFT AFT+IMP———16.7——0—260110—
Auclair et al, 201310CS4197AFT+IMP———5——92369.9 (n = 20)57% (12m)
Atia, 2020CS430AFT31.2326.91.21227—12—259.83ml 252.17 ml—
Auclair, 2020CS4148AFT+IMP4219.6—22——23—153ml—
Bircoll, 2010CS4650AFT——————8———
Brault et al, 201711CC3b1522AFT C:IMP21.1—217——2———
Bravo, 2014CC3b2138AFT+IMPC:IMP———12——2—117—
Bresnick, 2016CS428AFT——2.1—28—0-27—
Carvajal and Patino, 2008CS420AFT36.9——34.5——44235—
Chiu, 2014CS4205(HB) 77(LB)AFT+SVF34.9 31.221.2 17.6—23.7 23.01766517864137—254241—
Chiu, 2016CS427AFT+SVF39.119.9—27.1——6—247—
Chiu, 201816CC3b105 101AFT AFT+SVF333718.8 20.311.215.8 13.4——46—31033467.9% (12m) 68.7% (12m)
Claudio et al, 2017CS411AFT2423.4229.7——42210—
Coleman and Saboeiro, 200713CH2b17AFT38.2—1.262.2——102278.6—
Cotrufo et al, 2008CS442AFT48—1.37——1———
Del Vecchio and Bucky, 2011CH2b25AFT +BRAVA21–60——6——0—430 (n = 12)64% (6m)
Del Vecchio, 201419CS430AFT +BRAVA———12————30053% (12m)
Delay et al, 200918CS4136AFT——3–4120——4 (n = 880)——60~70% (3m)
Delay et al, 2013CS431AFT2321.91.57831290—158—
226
Derder et al, 201420CS410AFT17.5—26810———285—
Deschler et al, 202025CS442AFT3422.9—25.6——3—312.2ml—
Dos Anjos et al, 201517CC3b13 (LS) 44 (HS)AFT+SVF37.8 39.421.6 21.6—18——33229.1 270.750% (18m) 75% (18m)
Fiaschetti et al, 2013CH2b6AFT+PRP46.3—2—————195.684.4% (6m) 72.1% (12m)
Guo et al, 201821CH2b11AFT2720.213——0—20756.6% (3m)
Gutierrez-Ontalvilla et al, 2020CS49AFT14.9—1.821.3——1—220ml—
Herly et al, 2019CS414AFT34.924.214.5————304ml50.9% (4.5m)
Herold et al, 2010CH2b10AFT————————20872.0% (6m)
Ho Quoc et al, 201312CS41000AFT39—1–3———40———
Ho Quoc et al, 2015CS410AFT2121.5—7210—0—380—
Illouz and Sterodimas, 2009CS4439AFT45.6—312399—53—145—
Jung et al, 2016CH2b5AFT+SVF34.4——12——5(n=10)—221.265.1% (3m) 46.8% (12m)
Kamakura and Ito, 2011CH2b20AFT +ADRCS35.6——91511(n=16)21240—
Kang and Luan, 201814CH2b100AFT43.621.31.33——21 (n=167)—176.1—
Kerfant et al, 2017CS4156AFT+IMP31.718. 91.122.3——11—126—
Khouri et al, 2012CH2b81AFT +BRAVA17–6319.814481—1—282 (n=71)82.0% (12m)
Khouri et al, 2014CS44594AFT +BRAVAAFT27 45.221.61.2 1.494390——24—30035479.0% (12m) 64.0% (12m)
Klit et al, 20155CS44 7AFT +BRAVAAFT1820–251139—0—245 147—
La Marca et al, 2013CS410AFT16—2.95110—0—255—
Li et al, 2014CS4105AFT31.3—1.3181058853205—
Maione et al, 2018CH2b31AFT+IMP34.3—13–12——0—134—
Matsudo and Toledo, 1988CS421AFT———18———5–450ml20–50%
Muench, 2016CS4254AFT35.822.51.224.5246—11—207—
Münch, 2013CS484AFT36.722.71.14.783—9—177—
Ohashi et al, 2016CS4131AFT39.319.9—6126—12—239.6—
Özalp and Aydinol, 2017CS434AFT+IMP31——2230—6(n=68)—114—
Peltoniemi et al, 201315CH2b108AFT+ ASCSAFT513923.423.41.81.86——21—178.5 20474.2% (6m) 78.8% (6m)
Pinsolle et al, 2008CS471AFT1+IMP AFT25—2.1———1—96—
Quoc et al, 2013CS419AFT2820.31.6—18180—375—
Rubin et al, 2012CH2b27 23AFTC:reduction35.9——12————526.5—
Serra-Mestr et al, 2017CH2b49AFT41——1248—3142—
Sforza et al, 201622CS426AFT24———25230—14872.5% (12m)
Spear and Pittman, 201423CH2b10AFT3023.31———0124339.8 % (12m)
Tassinari et al, 2016CS5242AFT———26.4——37—136—
Ueberreiter et al, 2010CH2b52AFT——2.96–30——0—18476% (6m)
Ueberreiter et al, 2013CH2b56AFT22–5817–3036–5656———260—
Veber et al, 2011CH2b31AFT38—1.316.2-———200.8—
Visconti and Salgarello, 2019CC3b29AFT +BRAVA26.526.61.31240 in46—0—215ml—
Wang et al, 2011CS448AFT29.4——18–72——8850–170—
Wang et al, 2012CH2b18AFT+SVF3222.1—6——1—256.5 (n=10)51.2% (3m) 54.2% (6m)
Wang et al, 2015CH2b12AFT+SVF3222.1—611110—25660.7% (3m) 45.5% (6m)
Yoshimura et al, 20088CS440AFT+ CAL35.819.114240—1—272.755.9% (6m)
Yoshimura et al, 20109CS415AFT+ CAL37.119.511815—0—263.520~60% (n=6)
Zheng et al, 2008CS466AFT19–39—1.8375352132174—
Zheng et al, 2019CC3b5AFT29.621.11.24.4——0—175ml59.13%(4.4m)
Zocchi and Zuliani, 20086CH2b181AFT +BRAVA33——1217617112—37555% (12m)
Zocchi, 20177CS4388 99AFT +BRAVAAFT+SVF29.2 26.8——12——25—287 38074% (12m) 86% (12m)
StudyDesignLevelNo. patientsTreat groupAge(y)BMI kg/m2No. sessionsFellow-up (mo)Satisfaction No. PatientsSatisfaction No. SurgeonNo. ComplicationsNo. BiopsyMean Volume injection (ml)Volume retention(%)
Abboud and Dibo, 201524CH2b80AFT362612465 (n = 72)—11 (n = 160)1 (n = 160)42059.4% (12m)
Auclair, 2009CS41433AFT AFT+IMP———16.7——0—260110—
Auclair et al, 201310CS4197AFT+IMP———5——92369.9 (n = 20)57% (12m)
Atia, 2020CS430AFT31.2326.91.21227—12—259.83ml 252.17 ml—
Auclair, 2020CS4148AFT+IMP4219.6—22——23—153ml—
Bircoll, 2010CS4650AFT——————8———
Brault et al, 201711CC3b1522AFT C:IMP21.1—217——2———
Bravo, 2014CC3b2138AFT+IMPC:IMP———12——2—117—
Bresnick, 2016CS428AFT——2.1—28—0-27—
Carvajal and Patino, 2008CS420AFT36.9——34.5——44235—
Chiu, 2014CS4205(HB) 77(LB)AFT+SVF34.9 31.221.2 17.6—23.7 23.01766517864137—254241—
Chiu, 2016CS427AFT+SVF39.119.9—27.1——6—247—
Chiu, 201816CC3b105 101AFT AFT+SVF333718.8 20.311.215.8 13.4——46—31033467.9% (12m) 68.7% (12m)
Claudio et al, 2017CS411AFT2423.4229.7——42210—
Coleman and Saboeiro, 200713CH2b17AFT38.2—1.262.2——102278.6—
Cotrufo et al, 2008CS442AFT48—1.37——1———
Del Vecchio and Bucky, 2011CH2b25AFT +BRAVA21–60——6——0—430 (n = 12)64% (6m)
Del Vecchio, 201419CS430AFT +BRAVA———12————30053% (12m)
Delay et al, 200918CS4136AFT——3–4120——4 (n = 880)——60~70% (3m)
Delay et al, 2013CS431AFT2321.91.57831290—158—
226
Derder et al, 201420CS410AFT17.5—26810———285—
Deschler et al, 202025CS442AFT3422.9—25.6——3—312.2ml—
Dos Anjos et al, 201517CC3b13 (LS) 44 (HS)AFT+SVF37.8 39.421.6 21.6—18——33229.1 270.750% (18m) 75% (18m)
Fiaschetti et al, 2013CH2b6AFT+PRP46.3—2—————195.684.4% (6m) 72.1% (12m)
Guo et al, 201821CH2b11AFT2720.213——0—20756.6% (3m)
Gutierrez-Ontalvilla et al, 2020CS49AFT14.9—1.821.3——1—220ml—
Herly et al, 2019CS414AFT34.924.214.5————304ml50.9% (4.5m)
Herold et al, 2010CH2b10AFT————————20872.0% (6m)
Ho Quoc et al, 201312CS41000AFT39—1–3———40———
Ho Quoc et al, 2015CS410AFT2121.5—7210—0—380—
Illouz and Sterodimas, 2009CS4439AFT45.6—312399—53—145—
Jung et al, 2016CH2b5AFT+SVF34.4——12——5(n=10)—221.265.1% (3m) 46.8% (12m)
Kamakura and Ito, 2011CH2b20AFT +ADRCS35.6——91511(n=16)21240—
Kang and Luan, 201814CH2b100AFT43.621.31.33——21 (n=167)—176.1—
Kerfant et al, 2017CS4156AFT+IMP31.718. 91.122.3——11—126—
Khouri et al, 2012CH2b81AFT +BRAVA17–6319.814481—1—282 (n=71)82.0% (12m)
Khouri et al, 2014CS44594AFT +BRAVAAFT27 45.221.61.2 1.494390——24—30035479.0% (12m) 64.0% (12m)
Klit et al, 20155CS44 7AFT +BRAVAAFT1820–251139—0—245 147—
La Marca et al, 2013CS410AFT16—2.95110—0—255—
Li et al, 2014CS4105AFT31.3—1.3181058853205—
Maione et al, 2018CH2b31AFT+IMP34.3—13–12——0—134—
Matsudo and Toledo, 1988CS421AFT———18———5–450ml20–50%
Muench, 2016CS4254AFT35.822.51.224.5246—11—207—
Münch, 2013CS484AFT36.722.71.14.783—9—177—
Ohashi et al, 2016CS4131AFT39.319.9—6126—12—239.6—
Özalp and Aydinol, 2017CS434AFT+IMP31——2230—6(n=68)—114—
Peltoniemi et al, 201315CH2b108AFT+ ASCSAFT513923.423.41.81.86——21—178.5 20474.2% (6m) 78.8% (6m)
Pinsolle et al, 2008CS471AFT1+IMP AFT25—2.1———1—96—
Quoc et al, 2013CS419AFT2820.31.6—18180—375—
Rubin et al, 2012CH2b27 23AFTC:reduction35.9——12————526.5—
Serra-Mestr et al, 2017CH2b49AFT41——1248—3142—
Sforza et al, 201622CS426AFT24———25230—14872.5% (12m)
Spear and Pittman, 201423CH2b10AFT3023.31———0124339.8 % (12m)
Tassinari et al, 2016CS5242AFT———26.4——37—136—
Ueberreiter et al, 2010CH2b52AFT——2.96–30——0—18476% (6m)
Ueberreiter et al, 2013CH2b56AFT22–5817–3036–5656———260—
Veber et al, 2011CH2b31AFT38—1.316.2-———200.8—
Visconti and Salgarello, 2019CC3b29AFT +BRAVA26.526.61.31240 in46—0—215ml—
Wang et al, 2011CS448AFT29.4——18–72——8850–170—
Wang et al, 2012CH2b18AFT+SVF3222.1—6——1—256.5 (n=10)51.2% (3m) 54.2% (6m)
Wang et al, 2015CH2b12AFT+SVF3222.1—611110—25660.7% (3m) 45.5% (6m)
Yoshimura et al, 20088CS440AFT+ CAL35.819.114240—1—272.755.9% (6m)
Yoshimura et al, 20109CS415AFT+ CAL37.119.511815—0—263.520~60% (n=6)
Zheng et al, 2008CS466AFT19–39—1.8375352132174—
Zheng et al, 2019CC3b5AFT29.621.11.24.4——0—175ml59.13%(4.4m)
Zocchi and Zuliani, 20086CH2b181AFT +BRAVA33——1217617112—37555% (12m)
Zocchi, 20177CS4388 99AFT +BRAVAAFT+SVF29.2 26.8——12——25—287 38074% (12m) 86% (12m)

—, not reported; ADRCS, autologous adipose-derived regenerative cells; AFT, autologous fat transplantation; ASCs, adipose-derived stem cells; C, control group; CAL, cell-assisted lipotransfer; CC, case-control study; CH, cohort study; CS, case series study; FU, fellow-up; HB, high BMI (BMI > 18.5); HS, high stromal vascular fraction; IMP, implant; LB; low BMI (BMI ≤ 18.5); LS, low stromal vascular fraction; m, month; PRP, platelet-rich plasma; SUPP, supplements as SVF, CAL, PRP, or ASCs; SVF, stromal vascular fraction; VOL, volume; n, number of related cases.

Table 3.
Open in new tab

Baseline Table of All Studies

StudyDesignLevelNo. patientsTreat groupAge(y)BMI kg/m2No. sessionsFellow-up (mo)Satisfaction No. PatientsSatisfaction No. SurgeonNo. ComplicationsNo. BiopsyMean Volume injection (ml)Volume retention(%)
Abboud and Dibo, 201524CH2b80AFT362612465 (n = 72)—11 (n = 160)1 (n = 160)42059.4% (12m)
Auclair, 2009CS41433AFT AFT+IMP———16.7——0—260110—
Auclair et al, 201310CS4197AFT+IMP———5——92369.9 (n = 20)57% (12m)
Atia, 2020CS430AFT31.2326.91.21227—12—259.83ml 252.17 ml—
Auclair, 2020CS4148AFT+IMP4219.6—22——23—153ml—
Bircoll, 2010CS4650AFT——————8———
Brault et al, 201711CC3b1522AFT C:IMP21.1—217——2———
Bravo, 2014CC3b2138AFT+IMPC:IMP———12——2—117—
Bresnick, 2016CS428AFT——2.1—28—0-27—
Carvajal and Patino, 2008CS420AFT36.9——34.5——44235—
Chiu, 2014CS4205(HB) 77(LB)AFT+SVF34.9 31.221.2 17.6—23.7 23.01766517864137—254241—
Chiu, 2016CS427AFT+SVF39.119.9—27.1——6—247—
Chiu, 201816CC3b105 101AFT AFT+SVF333718.8 20.311.215.8 13.4——46—31033467.9% (12m) 68.7% (12m)
Claudio et al, 2017CS411AFT2423.4229.7——42210—
Coleman and Saboeiro, 200713CH2b17AFT38.2—1.262.2——102278.6—
Cotrufo et al, 2008CS442AFT48—1.37——1———
Del Vecchio and Bucky, 2011CH2b25AFT +BRAVA21–60——6——0—430 (n = 12)64% (6m)
Del Vecchio, 201419CS430AFT +BRAVA———12————30053% (12m)
Delay et al, 200918CS4136AFT——3–4120——4 (n = 880)——60~70% (3m)
Delay et al, 2013CS431AFT2321.91.57831290—158—
226
Derder et al, 201420CS410AFT17.5—26810———285—
Deschler et al, 202025CS442AFT3422.9—25.6——3—312.2ml—
Dos Anjos et al, 201517CC3b13 (LS) 44 (HS)AFT+SVF37.8 39.421.6 21.6—18——33229.1 270.750% (18m) 75% (18m)
Fiaschetti et al, 2013CH2b6AFT+PRP46.3—2—————195.684.4% (6m) 72.1% (12m)
Guo et al, 201821CH2b11AFT2720.213——0—20756.6% (3m)
Gutierrez-Ontalvilla et al, 2020CS49AFT14.9—1.821.3——1—220ml—
Herly et al, 2019CS414AFT34.924.214.5————304ml50.9% (4.5m)
Herold et al, 2010CH2b10AFT————————20872.0% (6m)
Ho Quoc et al, 201312CS41000AFT39—1–3———40———
Ho Quoc et al, 2015CS410AFT2121.5—7210—0—380—
Illouz and Sterodimas, 2009CS4439AFT45.6—312399—53—145—
Jung et al, 2016CH2b5AFT+SVF34.4——12——5(n=10)—221.265.1% (3m) 46.8% (12m)
Kamakura and Ito, 2011CH2b20AFT +ADRCS35.6——91511(n=16)21240—
Kang and Luan, 201814CH2b100AFT43.621.31.33——21 (n=167)—176.1—
Kerfant et al, 2017CS4156AFT+IMP31.718. 91.122.3——11—126—
Khouri et al, 2012CH2b81AFT +BRAVA17–6319.814481—1—282 (n=71)82.0% (12m)
Khouri et al, 2014CS44594AFT +BRAVAAFT27 45.221.61.2 1.494390——24—30035479.0% (12m) 64.0% (12m)
Klit et al, 20155CS44 7AFT +BRAVAAFT1820–251139—0—245 147—
La Marca et al, 2013CS410AFT16—2.95110—0—255—
Li et al, 2014CS4105AFT31.3—1.3181058853205—
Maione et al, 2018CH2b31AFT+IMP34.3—13–12——0—134—
Matsudo and Toledo, 1988CS421AFT———18———5–450ml20–50%
Muench, 2016CS4254AFT35.822.51.224.5246—11—207—
Münch, 2013CS484AFT36.722.71.14.783—9—177—
Ohashi et al, 2016CS4131AFT39.319.9—6126—12—239.6—
Özalp and Aydinol, 2017CS434AFT+IMP31——2230—6(n=68)—114—
Peltoniemi et al, 201315CH2b108AFT+ ASCSAFT513923.423.41.81.86——21—178.5 20474.2% (6m) 78.8% (6m)
Pinsolle et al, 2008CS471AFT1+IMP AFT25—2.1———1—96—
Quoc et al, 2013CS419AFT2820.31.6—18180—375—
Rubin et al, 2012CH2b27 23AFTC:reduction35.9——12————526.5—
Serra-Mestr et al, 2017CH2b49AFT41——1248—3142—
Sforza et al, 201622CS426AFT24———25230—14872.5% (12m)
Spear and Pittman, 201423CH2b10AFT3023.31———0124339.8 % (12m)
Tassinari et al, 2016CS5242AFT———26.4——37—136—
Ueberreiter et al, 2010CH2b52AFT——2.96–30——0—18476% (6m)
Ueberreiter et al, 2013CH2b56AFT22–5817–3036–5656———260—
Veber et al, 2011CH2b31AFT38—1.316.2-———200.8—
Visconti and Salgarello, 2019CC3b29AFT +BRAVA26.526.61.31240 in46—0—215ml—
Wang et al, 2011CS448AFT29.4——18–72——8850–170—
Wang et al, 2012CH2b18AFT+SVF3222.1—6——1—256.5 (n=10)51.2% (3m) 54.2% (6m)
Wang et al, 2015CH2b12AFT+SVF3222.1—611110—25660.7% (3m) 45.5% (6m)
Yoshimura et al, 20088CS440AFT+ CAL35.819.114240—1—272.755.9% (6m)
Yoshimura et al, 20109CS415AFT+ CAL37.119.511815—0—263.520~60% (n=6)
Zheng et al, 2008CS466AFT19–39—1.8375352132174—
Zheng et al, 2019CC3b5AFT29.621.11.24.4——0—175ml59.13%(4.4m)
Zocchi and Zuliani, 20086CH2b181AFT +BRAVA33——1217617112—37555% (12m)
Zocchi, 20177CS4388 99AFT +BRAVAAFT+SVF29.2 26.8——12——25—287 38074% (12m) 86% (12m)
StudyDesignLevelNo. patientsTreat groupAge(y)BMI kg/m2No. sessionsFellow-up (mo)Satisfaction No. PatientsSatisfaction No. SurgeonNo. ComplicationsNo. BiopsyMean Volume injection (ml)Volume retention(%)
Abboud and Dibo, 201524CH2b80AFT362612465 (n = 72)—11 (n = 160)1 (n = 160)42059.4% (12m)
Auclair, 2009CS41433AFT AFT+IMP———16.7——0—260110—
Auclair et al, 201310CS4197AFT+IMP———5——92369.9 (n = 20)57% (12m)
Atia, 2020CS430AFT31.2326.91.21227—12—259.83ml 252.17 ml—
Auclair, 2020CS4148AFT+IMP4219.6—22——23—153ml—
Bircoll, 2010CS4650AFT——————8———
Brault et al, 201711CC3b1522AFT C:IMP21.1—217——2———
Bravo, 2014CC3b2138AFT+IMPC:IMP———12——2—117—
Bresnick, 2016CS428AFT——2.1—28—0-27—
Carvajal and Patino, 2008CS420AFT36.9——34.5——44235—
Chiu, 2014CS4205(HB) 77(LB)AFT+SVF34.9 31.221.2 17.6—23.7 23.01766517864137—254241—
Chiu, 2016CS427AFT+SVF39.119.9—27.1——6—247—
Chiu, 201816CC3b105 101AFT AFT+SVF333718.8 20.311.215.8 13.4——46—31033467.9% (12m) 68.7% (12m)
Claudio et al, 2017CS411AFT2423.4229.7——42210—
Coleman and Saboeiro, 200713CH2b17AFT38.2—1.262.2——102278.6—
Cotrufo et al, 2008CS442AFT48—1.37——1———
Del Vecchio and Bucky, 2011CH2b25AFT +BRAVA21–60——6——0—430 (n = 12)64% (6m)
Del Vecchio, 201419CS430AFT +BRAVA———12————30053% (12m)
Delay et al, 200918CS4136AFT——3–4120——4 (n = 880)——60~70% (3m)
Delay et al, 2013CS431AFT2321.91.57831290—158—
226
Derder et al, 201420CS410AFT17.5—26810———285—
Deschler et al, 202025CS442AFT3422.9—25.6——3—312.2ml—
Dos Anjos et al, 201517CC3b13 (LS) 44 (HS)AFT+SVF37.8 39.421.6 21.6—18——33229.1 270.750% (18m) 75% (18m)
Fiaschetti et al, 2013CH2b6AFT+PRP46.3—2—————195.684.4% (6m) 72.1% (12m)
Guo et al, 201821CH2b11AFT2720.213——0—20756.6% (3m)
Gutierrez-Ontalvilla et al, 2020CS49AFT14.9—1.821.3——1—220ml—
Herly et al, 2019CS414AFT34.924.214.5————304ml50.9% (4.5m)
Herold et al, 2010CH2b10AFT————————20872.0% (6m)
Ho Quoc et al, 201312CS41000AFT39—1–3———40———
Ho Quoc et al, 2015CS410AFT2121.5—7210—0—380—
Illouz and Sterodimas, 2009CS4439AFT45.6—312399—53—145—
Jung et al, 2016CH2b5AFT+SVF34.4——12——5(n=10)—221.265.1% (3m) 46.8% (12m)
Kamakura and Ito, 2011CH2b20AFT +ADRCS35.6——91511(n=16)21240—
Kang and Luan, 201814CH2b100AFT43.621.31.33——21 (n=167)—176.1—
Kerfant et al, 2017CS4156AFT+IMP31.718. 91.122.3——11—126—
Khouri et al, 2012CH2b81AFT +BRAVA17–6319.814481—1—282 (n=71)82.0% (12m)
Khouri et al, 2014CS44594AFT +BRAVAAFT27 45.221.61.2 1.494390——24—30035479.0% (12m) 64.0% (12m)
Klit et al, 20155CS44 7AFT +BRAVAAFT1820–251139—0—245 147—
La Marca et al, 2013CS410AFT16—2.95110—0—255—
Li et al, 2014CS4105AFT31.3—1.3181058853205—
Maione et al, 2018CH2b31AFT+IMP34.3—13–12——0—134—
Matsudo and Toledo, 1988CS421AFT———18———5–450ml20–50%
Muench, 2016CS4254AFT35.822.51.224.5246—11—207—
Münch, 2013CS484AFT36.722.71.14.783—9—177—
Ohashi et al, 2016CS4131AFT39.319.9—6126—12—239.6—
Özalp and Aydinol, 2017CS434AFT+IMP31——2230—6(n=68)—114—
Peltoniemi et al, 201315CH2b108AFT+ ASCSAFT513923.423.41.81.86——21—178.5 20474.2% (6m) 78.8% (6m)
Pinsolle et al, 2008CS471AFT1+IMP AFT25—2.1———1—96—
Quoc et al, 2013CS419AFT2820.31.6—18180—375—
Rubin et al, 2012CH2b27 23AFTC:reduction35.9——12————526.5—
Serra-Mestr et al, 2017CH2b49AFT41——1248—3142—
Sforza et al, 201622CS426AFT24———25230—14872.5% (12m)
Spear and Pittman, 201423CH2b10AFT3023.31———0124339.8 % (12m)
Tassinari et al, 2016CS5242AFT———26.4——37—136—
Ueberreiter et al, 2010CH2b52AFT——2.96–30——0—18476% (6m)
Ueberreiter et al, 2013CH2b56AFT22–5817–3036–5656———260—
Veber et al, 2011CH2b31AFT38—1.316.2-———200.8—
Visconti and Salgarello, 2019CC3b29AFT +BRAVA26.526.61.31240 in46—0—215ml—
Wang et al, 2011CS448AFT29.4——18–72——8850–170—
Wang et al, 2012CH2b18AFT+SVF3222.1—6——1—256.5 (n=10)51.2% (3m) 54.2% (6m)
Wang et al, 2015CH2b12AFT+SVF3222.1—611110—25660.7% (3m) 45.5% (6m)
Yoshimura et al, 20088CS440AFT+ CAL35.819.114240—1—272.755.9% (6m)
Yoshimura et al, 20109CS415AFT+ CAL37.119.511815—0—263.520~60% (n=6)
Zheng et al, 2008CS466AFT19–39—1.8375352132174—
Zheng et al, 2019CC3b5AFT29.621.11.24.4——0—175ml59.13%(4.4m)
Zocchi and Zuliani, 20086CH2b181AFT +BRAVA33——1217617112—37555% (12m)
Zocchi, 20177CS4388 99AFT +BRAVAAFT+SVF29.2 26.8——12——25—287 38074% (12m) 86% (12m)

—, not reported; ADRCS, autologous adipose-derived regenerative cells; AFT, autologous fat transplantation; ASCs, adipose-derived stem cells; C, control group; CAL, cell-assisted lipotransfer; CC, case-control study; CH, cohort study; CS, case series study; FU, fellow-up; HB, high BMI (BMI > 18.5); HS, high stromal vascular fraction; IMP, implant; LB; low BMI (BMI ≤ 18.5); LS, low stromal vascular fraction; m, month; PRP, platelet-rich plasma; SUPP, supplements as SVF, CAL, PRP, or ASCs; SVF, stromal vascular fraction; VOL, volume; n, number of related cases.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close